SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.

Fabio Salvatore MacalusoMaria CappelloAnita BusaccaWalter FriesAnna ViolaGiuseppe CostantinoAntonio MagnanoElisa VinciConcetta FerracaneAntonino Carlo PriviteraGiovita PiccilloNunzio BelluardoEmiliano GiangrecoClaudio RomanoMichele CitranoFrancesco GrazianoSerena GarufiCarmelo BertolamiMarco VentimigliaBarbara ScrivoGiulia TeresiSara RennaGiulia RizzutoAngelo CasàAmbrogio Orlandonull null

Published in: Journal of gastroenterology and hepatology (2021)

Safety and effectiveness of ABP 501 seem to be overall similar to those reported for ADA originator. Switching from originator to ABP 501 was safe and effective.

Keyphrases

patients with inflammatory bowel disease
randomized controlled trial
rheumatoid arthritis
systematic review
juvenile idiopathic arthritis